DARE - Daré Bioscience, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.8550
+0.0150 (+1.79%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.8400
Open0.8700
Bid0.800 x 1300
Ask0.900 x 1300
Day's Range0.8500 - 0.8989
52 Week Range0.6000 - 3.5900
Volume66,771
Avg. Volume252,481
Market Cap9.766M
Beta (3Y Monthly)3.15
PE Ratio (TTM)N/A
EPS (TTM)-2.444
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • GlobeNewswire18 days ago

    Daré Bioscience Provides Update for Investors on Development Programs and Anticipated 2019 Milestones

    Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, today provided an update on its product portfolio for investors that includes anticipated 2019 clinical milestones. “2018 was a year of substantial execution as we assembled a broad and differentiated pipeline of product candidates across women’s health,” stated Sabrina Martucci Johnson, President and Chief Executive Officer of Daré.

  • What Kind Of Investor Owns Most Of Daré Bioscience, Inc. (NASDAQ:DARE)?
    Simply Wall St.26 days ago

    What Kind Of Investor Owns Most Of Daré Bioscience, Inc. (NASDAQ:DARE)?

    The big shareholder groups in Daré Bioscience, Inc. (NASDAQ:DARE) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their Read More...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of DARE earnings conference call or presentation 13-Nov-18 1:30pm GMT

    Q3 2018 Dare Bioscience Inc Earnings Call

  • Zacks Small Cap Researchlast month

    DARE: DARE Adds Late-Stage Bacterial Vaginosis Candidate To Ever-Expanding Women’s Health Pipeline

    Dare Bioscience (DARE) is showing no signs of slowing down as it relates to expanding their women’s health focused pipeline and their potential eventual related commercialization opportunities. Hammock Pharmaceuticals, Inc., TriLogic Pharma LLC and MilanaPharm LLC. DARE is also required to pay potential future milestones based on “clinical, regulatory, commercial launch and sales events”, and is also subject to paying royalties on any eventual sales. Bacterial Vaginosis, What It Is, How Prevalent and How Is it Treated?

  • ACCESSWIRElast month

    New Healthcare Trends Pushing Stocks Higher On Thursday

    CORAL GABLES, FL / ACCESSWIRE / December 6, 2018 / Analyst firms like Global Market Insights are expecting a lot as far as the future of healthcare is concerned. The firm reports that the healthcare industry ...

  • GlobeNewswirelast month

    Daré Bioscience, Inc. Announces Licensing and Global Rights to Novel Phase III Product Candidate for the Treatment of Bacterial Vaginosis

    Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, today announced that it has entered into definitive agreements with Hammock Pharmaceuticals, Inc., TriLogic Pharma LLC and MilanaPharm LLC under which Daré acquired the global rights to MP-101 for the treatment of bacterial vaginosis (BV), as well as the rights to utilize the underlying proprietary hydrogel drug delivery technology for any vaginal or urological application in humans.

  • Zacks Small Cap Research2 months ago

    DARE: Ovaprene PCT Continues. TS Content Validity Study, Thermographic Study Underway

    By Brian Marckx, CFA NASDAQ:DARE READ THE FULL DARE RESEARCH REPORT Q3 / Pipeline Update Daré (NASDAQ:DARE) reported financial results for their third quarter and provided an operational update. Relative ...

  • GlobeNewswire2 months ago

    Daré Bioscience, Inc. Announces Initiation of Content Validity Study for Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

    Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the initiation of a content validity study intended to support the use of specific patient reported outcome (PRO) measures to assess efficacy in female sexual arousal disorder (FSAD) patients in the Phase 2b and Phase 3 program for Sildenafil Cream, 3.6%.

  • GlobeNewswire2 months ago

    Daré Bioscience, Inc. Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

    Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, today announced that it is currently enrolling patients in an investigational study designed to evaluate the feasibility of using thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6% in normal healthy women. Sildenafil, the active ingredient in Sildenafil Cream, 3.6%, is marketed in an oral dosage form under the brand name Viagra® for the treatment of erectile dysfunction in men.

  • GlobeNewswire2 months ago

    Daré Bioscience Provides Business Update and Announces Third Quarter Financial Results

    SAN DIEGO, Nov. 13, 2018 -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today provided a business update and announced financial.

  • GlobeNewswire2 months ago

    Daré to Host Third Quarter 2018 Financial Results Conference Call and Webcast

    Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will host a conference call and live webcast at 8:30 a.m. Eastern Time on Tuesday, November 13, 2018, to provide a corporate update and to discuss the Company's financial results for the quarter ended September 30, 2018. To access the conference call via phone, dial (844) 831-3031 (domestic) or (443) 637-1284 (International). The conference ID number for the call is 5463588.

  • GlobeNewswire3 months ago

    Daré Bioscience, Inc. to Present at the Dawson James Small Cap Growth Conference

    SAN DIEGO, Oct. 23, 2018 -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair, Chief Business Officer,.

  • Zacks Small Cap Research4 months ago

    DARE: Upcoming Milestones Inc FDA Feedback on Topical Sildenafil FSAD Program

    Daré (DARE) continues to not only move their various development programs forward, but also continues to add promising candidates to their high-potential women’s health-focused pipeline. Relative to the latter, DARE’s most recent pipeline addition, CatSper, a potential first-in-kind contraceptive for both men and women, was announced in mid-July.

  • ACCESSWIRE6 months ago

    Daré Bioscience, Growing Through Collaborations, Male Contraceptive, Analysts Target

    NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Daré Bioscience (DARE), a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's reproductive health. Daré's lead product candidate, Ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies. On July 16th, the company announced that it has entered into an asset transfer agreement with Hydra Biosciences, Inc. for the transfer of all of Hydra's interest in certain intellectual property relating to Hydra's CatSper ion channel target portfolio.

  • ACCESSWIRE7 months ago

    Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on DERM sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Daré Bioscience Inc. (NASDAQ: DARE), Dermira Inc. (NASDAQ: DERM), Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA), and Egalet Corp. (NASDAQ: EGLT).

  • Zacks Small Cap Research8 months ago

    DARE: Initiating Coverage of DARE With $6.75/share Price Target

    DARE is a pre-revenue, clinical-stage company engaged in the development of novel therapeutic technologies targeting unmet needs in women’s health. In July 2017, DARE obtained worldwide rights (licensed from ADVA-Tec) to Ovaprene, the company’s lead development program. While certain features of vaginal rings (including effectiveness, reversibility and convenience of monthly use) score high in consumer surveys and studies, hormone-related side-effects (including risk of serious cardiovascular events) are an oft-cited drawback of currently available options, such as NuvaRing (etonogestrel/ethinyl estradiol).